N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester | 851205-58-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester
• 英文别名: N'-(5-bromo-2-hydroxybenzyl)hydrazinecarboxylic acid tert-butyl ester；1,1-dimethylethyl 2-[(5-bromo-2-hydroxyphenyI)methyl]hydrazinecarboxylate；1,1-dimethylethyl 2-[(5-bromo-2-hydroxyphenyl)methyl]hydrazinecarboxylate；tert-butyl N-[(5-bromo-2-hydroxyphenyl)methylamino]carbamate
• CAS: 851205-58-8
• 化学式: C₁₂H₁₇BrN₂O₃
• 分子量: 317.183
• InChiKey: DXULBGNBIJFEBX-UHFFFAOYSA-N

物化性质

• 密度：
  1.415±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  70.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester 在 sodium hydroxide 、 溶剂黄146 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 ethyl 1-[(5-bromo-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)methyl]-5-methyl-1H-pyrazole-3-carboxylate
  参考文献：
  名称：

  Identification of novel pyrazole acid antagonists for the EP1 receptor

  摘要：

  The discovery, synthesis and structure-activity relationship (SAR) of a novel series of EP1 receptor antagonists is described. Pyrazole acid 4, identified from a chemical array, had desirable physicochemical properties, an excellent in vitro microsomal inhibition and cytochrome P450 (CYP450) profile and good exposure levels in blood. This compound had an ED50 of 1.3 mg/kg in a rat pain model. A range of more potent analogues in the in vitro assay was identified using efficient array chemistry. These EP1 antagonists have potential as agents in the treatment of PGE(2) mediated pain. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.086
• 作为产物：
  描述：

  N'-[1-(5-Bromo-2-hydroxy-phenyl)-meth-(E)-ylidene]-hydrazinecarboxylic acid tert-butyl ester 在 三乙酰氧基硼氢化钠 作用下， 生成 N'-(5-bromo-2-hydroxy-benzyl)-hydrazinecarboxylic acid tert-butyl ester
  参考文献：
  名称：

  Identification of novel pyrazole acid antagonists for the EP1 receptor

  摘要：

  The discovery, synthesis and structure-activity relationship (SAR) of a novel series of EP1 receptor antagonists is described. Pyrazole acid 4, identified from a chemical array, had desirable physicochemical properties, an excellent in vitro microsomal inhibition and cytochrome P450 (CYP450) profile and good exposure levels in blood. This compound had an ED50 of 1.3 mg/kg in a rat pain model. A range of more potent analogues in the in vitro assay was identified using efficient array chemistry. These EP1 antagonists have potential as agents in the treatment of PGE(2) mediated pain. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.06.086

文献信息

• COMPOUNDS ACTING AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE
  申请人：Allergan, Inc.

  公开号：US20130165492A1

  公开（公告）日：2013-06-27

  The present invention provides a compound, that is wherein Y, W, Z, R1, R2, R4, R5 and R6 are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.

  本发明提供了一种化合物，其中Y、W、Z、R1、R2、R4、R5和R6的定义如规范中所述。这些化合物可以用于治疗DP、FP、EP1、TP和/或EP4受体介导的疾病或症状。
• [EN] HETEROCYCLYL COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLYLES
  申请人：GLAXO GROUP LTD

  公开号：WO2005040128A1

  公开（公告）日：2005-05-06

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein W, X, Y, Z, R1, R2a, R2b, and Rx, R8, and R9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中W、X、Y、Z、R1、R2a、R2b、Rx、R8和R9如规范中定义，制备这种化合物的方法，包含这种化合物的药物组合物以及这种化合物在医学中的用途。
• PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS
  申请人：Conway Elizabeth Ann

  公开号：US20090239845A1

  公开（公告）日：2009-09-24

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R 1 , R 2a , R 2b , R 10 , R 11 and R x are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  公式（I）的化合物或其药学上可接受的衍生物：其中Z、R1、R2a、R2b、R10、R11和Rx的定义如规范所述，制备这种化合物的过程，包含这种化合物的药物组合物以及这种化合物在医学上的用途。
• Heterocyclyl compounds
  申请人：Giblin Martin Paul Gerard

  公开号：US20070060596A1

  公开（公告）日：2007-03-15

  Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein W, X, Y, Z, R 1 , R 2a , R 2b , and R x , R 8 and R 9 are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

  式(I)或其药学上可接受的衍生物的化合物： 其中W、X、Y、Z、R1、R2a、R2b和Rx、R8和R9如规范中所定义，制备这种化合物的过程，包括这种化合物的制药组合物以及这种化合物在医学上的应用。
• Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
  申请人：Allergan, Inc.

  公开号：US09035071B2

  公开（公告）日：2015-05-19

  The present invention provides a compound that is represented by the following general formula wherein R1, R2, R4, R5, R6, R7, X, W, X and Y are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions.

  本发明提供一种化合物，其由以下一般式表示：其中R1、R2、R4、R5、R6、R7、X、W、X和Y如规范中所定义。这些化合物可用于治疗DP1、FP、EP1、TP和/或EP4受体介导的疾病或情况。